AbbVie talks next steps as first Humira competitor makes it to market
In AbbVie’s first earnings call since Humira’s first biosimilar came to market earlier this year, CEO Rick Gonzalez touted just over $58 billion in revenue for the Big Pharma in 2022 — and laid out guidance for how the company will fare over the next two years, despite the loss of its Humira monopoly.
After touting AbbVie’s more than doubling of its R&D budget, the CEO said the company is “well positioned to absorb the impact from the Humira LOE and quickly return to robust sales growth in 2025.” The company also said it is expecting to see Humira sales drop by 37% in 2023.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.